Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Sells 1,500 Shares Under 10b5-1 Trading Plan
SEC Form 4
Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold 1,500 ordinary shares at $123.75 per share on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Bruce Cozadd, the Chairman and CEO of Jazz Pharmaceuticals, executed a sale of 1,500 ordinary shares on April 1, 2025.
- The sale was conducted at a price of $123.75 per share.
- This transaction was carried out under a pre-existing Rule 10b5-1 trading plan.
- Following the transaction, Cozadd directly owns 440,307 ordinary shares of Jazz Pharmaceuticals.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the executive's outlook on the company.
Industry Context
Sales by company executives are a normal part of corporate governance. Investors often look to the reasons behind the sale to determine if there is a negative outlook for the company.
Stakeholder Impact
- The sale of shares by a high-ranking executive could cause concern among shareholders, but the existence of a 10b5-1 trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: Bruce Cozadd sold 1,500 ordinary shares. |
| 04/03/2025 | Date of report. |
Keywords
Jazz Pharmaceuticals, Bruce Cozadd, share sale, Form 4, Rule 10b5-1, insider trading, JAZZ
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.